Breast Cancer

Oncology 17 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Breast Cancer has 17 FDA-approved novel treatments, led by Roche, with 1516 active industry clinical trials across 33 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Breast Cancer Market Leaders

Companies with the most FDA-approved novel Breast Cancer drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

AZD9833

AstraZeneca

Estimated · aging NCT04711252

Q4 2026

JSKN003

Shanghai JMT-Bio Inc.

Estimated · stale NCT06846437

Q4 2026

Afuresertib

Laekna Limited

Estimated · fresh NCT04851613

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Breast Cancer Treatments by Mechanism

Top 12 mechanisms across 126 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

46 trials 20 active 12 sponsors

PIK3CA

9 trials 4 active 2 sponsors

Trop-2

5 trials 4 active 1 sponsor

Estrogen Receptor Antagonist

11 trials 2 active 5 sponsors

Poly(ADP-Ribose) Polymerase Inhibitor

6 trials 2 active 1 sponsor

AKT1/AKT2/AKT3

3 trials 2 active 1 sponsor

Microtubule Inhibitor

17 trials 1 active 9 sponsors

Programmed Death Receptor-1 Blocking Antibody

13 trials 1 active 5 sponsors

Aromatase Inhibitor

7 trials 1 active 5 sponsors

Nucleoside Metabolic Inhibitor

7 trials 1 active 4 sponsors

Endoglycosidase

1 trials 1 active 1 sponsor

Hypoxia-inducible Factor Inhibitor

1 trials 1 active 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Breast Cancer Clinical Pipeline by Phase

1313 industry-sponsored trials across 484 sponsors

View full landscape →

Showing 30 of 30 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Roche	—	—	RECRUITING	2026-09-30	NCT06274515
AstraZeneca	Trastuzumab deruxtecan	—	RECRUITING	2026-10-31	NCT06429761
Novartis	Ribociclib	—	ACTIVE NOT RECRUITING	2030-06-28	NCT05161195
GE Healthcare	18F Fluoroestradiol Radiopharmaceutical with PET/CT	—	ACTIVE NOT RECRUITING	2025-04-18	NCT05486182
Jiangsu Famous Medical Technology Co., Ltd.	Dalpiciclib	—	NOT YET RECRUITING	2025-10-30	NCT06613373
Novartis	Alpelisib	PIK3CA	COMPLETED	2025-06-12	NCT05631795
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2022-09-30	NCT04330040
Roche	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2021-06-24	NCT02419742
Roche	Trastuzumab emtansine	—	COMPLETED	2019-12-14	NCT02658734
Pfizer	Palbociclib	Kinase Inhibitor [EPC]	COMPLETED	2019-07-25	NCT02679755
Lupin Ltd.	Lupin's Pegfilgrastim	—	COMPLETED	2019-01-09	NCT03511378
Roche	Docetaxel	Microtubule Inhibitor [EPC]	COMPLETED	2018-09-26	NCT02445586
iOMEDICO AG	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2017-08-31	NCT02248571
Novartis	RAD001	—	COMPLETED	2016-08-15	NCT01743560
AstraZeneca	Fulvestrant	Estrogen Receptor Antagonist [EPC]	COMPLETED	2016-05-06	NCT02447328
Agendia	TAC chemotherapy	—	COMPLETED	2016-02	NCT01501487
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	PEG-rhG-CSF	—	COMPLETED	2016-02	NCT02805205
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	PEG-rhG-CSF	—	COMPLETED	2016-02	NCT02805153
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2015-12	NCT01094184
Eisai Korea Inc.	Eribulin mesylate	Tubulin	COMPLETED	2015-07	NCT01961544
Xoft, Inc.	—	—	COMPLETED	2015-01	NCT00742222
Roche	Docetaxel	Microtubule Inhibitor [EPC]	COMPLETED	2014-07	NCT01301729
Novartis	Zoledronic acid	Farnesyl pyrophosphate synthase	COMPLETED	2012-08	NCT01129336
Novartis	letrozole	Aromatase Inhibitor [EPC]	COMPLETED	2009-06	NCT00688909
Ethicon, Inc.	—	—	COMPLETED	2009-03	NCT00768222
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	TERMINATED	2020-08-11	NCT04031885
SenoRx, Inc.	—	—	TERMINATED	2011-03	NCT00699101
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	WITHDRAWN	2022-03-23	NCT03988114
Roche	bevacizumab [Avastin]	—	WITHDRAWN	2013-11	NCT00774241
Roche	bevacizumab [Avastin]	—	WITHDRAWN	2012-12	NCT01156961

Showing 100 of 290 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shanghai JMT-Bio Inc.	JSKN003	—	RECRUITING	2026-10-13	NCT06846437
Natureceuticals Sdn Bhd	Nuvastatic 300	—	RECRUITING	2026-10-30	NCT07669467
InventisBio Co., Ltd	D-0502	—	RECRUITING	2026-11-30	NCT06954961
Greenwich LifeSciences, Inc.	GLSI-100	—	RECRUITING	2026-12	NCT05232916
Akeso	AK112	—	RECRUITING	2026-12	NCT06767527
Shandong Suncadia Medicine Co., Ltd.	HRS-8080 Tablet	—	RECRUITING	2026-12	NCT07024173
Shanghai Pharmaceuticals Holding Co., Ltd	SPH4336 Tablets	—	RECRUITING	2026-12-01	NCT05860465
Shanghai JMT-Bio Inc.	KN026	—	RECRUITING	2026-12-16	NCT06747338
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	RECRUITING	2026-12-31	NCT06081959
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2026-12-31	NCT05894239
Roche	Giredestrant	—	RECRUITING	2027-02-19	NCT06065748
LeonaBio	Lasofoxifene in combination with abemaciclib	—	RECRUITING	2027-04	NCT05696626
AstraZeneca	Camizestrant	—	RECRUITING	2027-04-20	NCT05774951
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2027-05	NCT06957886
Qilu Pharmaceutical Co., Ltd.	ESG401	—	RECRUITING	2027-06	NCT06732323
Qilu Pharmaceutical Co., Ltd.	ESG401	—	RECRUITING	2027-06-30	NCT06383767
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	RECRUITING	2027-07	NCT07071337
Biotheus Inc.	PM8002	—	RECRUITING	2027-07	NCT06419621
Pfizer	PF-07248144	—	RECRUITING	2027-07-22	NCT07062965
AstraZeneca	Dato-DXd	—	RECRUITING	2027-07-28	NCT06103864
Daiichi Sankyo	Trastuzumab Deruxtecan	—	RECRUITING	2027-10-01	NCT05950945
AstraZeneca	Capivasertib	AKT1/AKT2/AKT3	RECRUITING	2027-11-01	NCT04862663
BriaCell Therapeutics Corporation	SV-BR-1-GM	—	RECRUITING	2027-12	NCT06072612
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 for Injection	—	RECRUITING	2027-12	NCT07196774
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	RECRUITING	2027-12-31	NCT07461454
Shanghai Henlius Biotech	HLX87 + HLX22	—	RECRUITING	2028-01-15	NCT07294508
AstraZeneca	Dato-DXd	—	RECRUITING	2028-02-02	NCT07205822
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1811 for Injection	—	RECRUITING	2028-03	NCT07111832
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 Injection	—	RECRUITING	2028-03	NCT07008976
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2028-04-28	NCT06435429
Relay Therapeutics, Inc.	RLY-2608	—	RECRUITING	2028-04-30	NCT06982521
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2930+ chemotherapy	—	RECRUITING	2028-06	NCT07047365
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0270	—	RECRUITING	2028-08-31	NCT06680921
Olema Pharmaceuticals, Inc.	Palazestrant	—	RECRUITING	2028-12	NCT07085767
Shandong Suncadia Medicine Co., Ltd.	HRS-8080 Tablet ; Dalpiciclib Isethionate	—	RECRUITING	2028-12	NCT07354022
AstraZeneca	Saruparib (AZD5305)	—	RECRUITING	2029-03-30	NCT06380751
Celcuity Inc	Arm A: Gedatolisib + Palbociclib + Fulvestrant	—	RECRUITING	2029-03-31	NCT06757634
BeOne Medicines	BGB-43395	—	RECRUITING	2029-04	NCT07492641
Risen (Suzhou) Pharma Tech Co., Ltd.	JS105	—	RECRUITING	2029-05-31	NCT07207070
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 for Injection	—	RECRUITING	2029-07	NCT07003074
Stemline Therapeutics, Inc.	Elacestrant	—	RECRUITING	2029-08	NCT06492616
Novartis	Ribociclib	—	RECRUITING	2029-09-07	NCT05827081
AstraZeneca	Camizestrant	—	RECRUITING	2030-03-04	NCT05952557
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2030-04	NCT06126640
Shandong Suncadia Medicine Co., Ltd.	HRS-8080 Tablets	—	RECRUITING	2030-12	NCT07349069
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2032-05-30	NCT06790693
Shanghai JMT-Bio Inc.	KN026	—	RECRUITING	2034-08-07	NCT07441460
Olema Pharmaceuticals, Inc.	Palazestrant	—	RECRUITING	2026-06-30	NCT06016738
Shanghai Pharmaceuticals Holding Co., Ltd	SPH4336 Tablets 400mg	—	RECRUITING	2026-05-31	NCT05744687
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN003	—	RECRUITING	2026-04-01	NCT06079983
Genor Biopharma Co., Ltd.	GB491 combined with Letrozole	—	RECRUITING	2026-01-30	NCT05851014
BeBetter Med Inc	BEBT-209 capsules	—	RECRUITING	2025-12-31	NCT06998108
Tianjin Hemay Pharmaceutical Co., Ltd	Hemay022+AI	—	RECRUITING	2025-12	NCT06313983
Shanghai Yizhong Pharmaceutical Co., Ltd.	Paclitaxel Polymeric Micelles for Injection	—	RECRUITING	2025-12	NCT06143553
Shanghai JMT-Bio Inc.	Recombinant Humanized Bispecific antibody against HER2，KN026	—	RECRUITING	2025-07-31	NCT05838066
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2025-01-30	NCT05814354
AstraZeneca	AZD9833	—	ACTIVE NOT RECRUITING	2026-08-24	NCT04711252
Laekna Limited	Afuresertib	—	ACTIVE NOT RECRUITING	2026-10-30	NCT04851613
AstraZeneca	Capivasertib	AKT1/AKT2/AKT3	ACTIVE NOT RECRUITING	2026-10-31	NCT06635447
Immutep S.A.S.	eftilagimod alpha	—	ACTIVE NOT RECRUITING	2026-10-31	NCT05747794
Jiangsu HengRui Medicine Co., Ltd.	SHR6390	—	ACTIVE NOT RECRUITING	2026-10-31	NCT04842617
Roche	Inavolisib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-11-13	NCT05646862
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen	—	ACTIVE NOT RECRUITING	2026-12	NCT05780567
Gilead	Sacituzumab Govitecan-hziy	Trop-2	ACTIVE NOT RECRUITING	2026-12	NCT04639986
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Raloxifene - Usual	—	ACTIVE NOT RECRUITING	2026-12-18	NCT06062810
Pfizer	Vepdegestrant (ARV-471/PF-07850327)	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05909397
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05424835
Novartis	Alpelisib	PIK3CA	ACTIVE NOT RECRUITING	2027-01-28	NCT05038735
Novartis	Alpelisib	PIK3CA	ACTIVE NOT RECRUITING	2027-02-26	NCT04208178
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-04-06	NCT04421963
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2027-09-20	NCT05629585
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 Injection	—	ACTIVE NOT RECRUITING	2027-10	NCT06057610
Roche	Phesgo	Endoglycosidase [EPC]	ACTIVE NOT RECRUITING	2027-10-31	NCT05296798
AstraZeneca	Fulvestrant	Estrogen Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-12-31	NCT06764186
Gilead	Sacituzumab Govitecan-hziy	Trop-2	ACTIVE NOT RECRUITING	2028-04	NCT05840211
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2028-08-31	NCT04873362
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2028-11-20	NCT06112379
Pfizer	PF-07220060	—	ACTIVE NOT RECRUITING	2029-01-02	NCT06760637
Novartis	Ribociclib	—	ACTIVE NOT RECRUITING	2030-05-29	NCT03701334
Merck	Pembrolizumab (K)	—	ACTIVE NOT RECRUITING	2031-01-24	NCT03725059
AstraZeneca	Trastuzumab deruxtecan	—	ACTIVE NOT RECRUITING	2026-07-06	NCT04784715
Celcuity Inc	Gedatolisib	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05501886
DualityBio Inc.	DB-1303/BNT323	—	ACTIVE NOT RECRUITING	2026-06	NCT06018337
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	ACTIVE NOT RECRUITING	2026-05	NCT06343948
Tolmar Inc.	TOL2506	—	ACTIVE NOT RECRUITING	2026-04-30	NCT04906395
Roche	Giredestrant	—	ACTIVE NOT RECRUITING	2026-01-30	NCT04546009
Xuanzhu Biopharmaceutical Co., Ltd.	XZP-3287+ Letrozole/Anastrozole	—	ACTIVE NOT RECRUITING	2025-12-05	NCT05257395
Changchun GeneScience Pharmaceutical Co., Ltd.	T Leuprolide Injectable Emulsion	—	ACTIVE NOT RECRUITING	2025-11	NCT06449027
R-Pharm	RPH-051	—	ACTIVE NOT RECRUITING	2025-10-23	NCT07386938
Seagen, a wholly owned subsidiary of Pfizer	Tucatinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2025-09-05	NCT05132582
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2025-08-25	NCT05374512
Roche	Giredestrant	—	ACTIVE NOT RECRUITING	2025-08-08	NCT04961996
Roche	Giredestrant	—	ACTIVE NOT RECRUITING	2025-07-16	NCT05306340
Daiichi Sankyo	DS-8201a	—	ACTIVE NOT RECRUITING	2025-07-02	NCT04622319
AstraZeneca	AZD9833	—	ACTIVE NOT RECRUITING	2025-06-30	NCT04964934
Biocad	BCD-178	—	ACTIVE NOT RECRUITING	2025-06-06	NCT05802225
AstraZeneca	Trastuzumab Deruxtecan	—	ACTIVE NOT RECRUITING	2025-03-12	NCT05113251
Pfizer	ARV-471	—	ACTIVE NOT RECRUITING	2025-01-31	NCT05654623
BioRay Pharmaceutical Co., Ltd.	HS627	—	ACTIVE NOT RECRUITING	2024-09-11	NCT04514419
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2024-07-24	NCT05104866

Showing 100 of 545 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 should be intravenously infused	—	RECRUITING	2026-07-30	NCT06439771
Jacobio Pharmaceuticals Co., Ltd.	JAB-2485 (Aurora A inhibitor)	—	RECRUITING	2026-08	NCT05490472
AtlasMedx, Incorporated	AMXI-5001:Dose Escalation Phase I	—	RECRUITING	2026-08	NCT04503265
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-08-15	NCT04585750
Nantong Bencao Quadriga Medical Technology Co. Ltd.	NBQ72S	—	RECRUITING	2026-08-31	NCT06810804
Phoenix Molecular Designs	PMD-026	—	RECRUITING	2026-09	NCT04115306
Processa Pharmaceuticals	PCS6422 and capecitabine	—	RECRUITING	2026-09	NCT06568692
Abscint NV/SA	—	—	RECRUITING	2026-09	NCT06369831
TYK Medicines, Inc	TYK-00540	—	RECRUITING	2026-09	NCT06950086
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 for injection; Toripalimab injection	—	RECRUITING	2026-09-01	NCT07169994
RemeGen Co., Ltd.	Disitamab Vedotin	—	RECRUITING	2026-10-01	NCT06642545
Shandong Suncadia Medicine Co., Ltd.	HRS-2189	—	RECRUITING	2026-10-30	NCT06679036
Shandong Suncadia Medicine Co., Ltd.	HRS-8080; SHR-A1811	—	RECRUITING	2026-10-31	NCT06222879
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 should be intravenously infused	—	RECRUITING	2026-11	NCT06107686
Atossa Therapeutics, Inc.	(Z)-endoxifen	—	RECRUITING	2026-11	NCT05607004
SynDevRx, Inc.	Evexomostat	—	RECRUITING	2026-12	NCT05455619
858 Therapeutics, Inc.	ETX-19477	—	RECRUITING	2026-12	NCT06395519
Jiangsu HengRui Medicine Co., Ltd.	HRS-6209 Capsules	—	RECRUITING	2026-12	NCT06974929
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-12	NCT06042894
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB2930 for injection	—	RECRUITING	2026-12	NCT06202261
Shanghai Pharmaceuticals Holding Co., Ltd	SPH4336 Tablets	—	RECRUITING	2026-12-31	NCT05872347
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2026-12-31	NCT06695845
Rhizen Pharmaceuticals SA	Tenalisib	—	RECRUITING	2026-12-31	NCT06189209
Marengo Therapeutics, Inc.	STAR0602	—	RECRUITING	2027-01	NCT06827613
Biostar Pharma, Inc.	Utidelone	—	RECRUITING	2027-01-15	NCT06764940
Beijing Biotech	Dual-target CAR-NK cells (EB-DT-CAR-NK)	—	RECRUITING	2027-02-14	NCT07486089
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-03-14	NCT07510802
ITM Oncologics GmbH	[68Ga]Ga-DPI-4452	—	RECRUITING	2027-06	NCT05706129
Criterium, Inc.	Tucatinib	Kinase Inhibitor [EPC]	RECRUITING	2027-06-01	NCT05458674
Shanghai Henlius Biotech	HLX22	—	RECRUITING	2027-06-01	NCT06832202
Ensem Therapeutics	ETX-636 dose escalation	—	RECRUITING	2027-06-30	NCT06993844
TransThera Sciences (Nanjing), Inc.	Tinengotinib at the optimal dose combined with Fulvestrant	—	RECRUITING	2027-06-30	NCT07498478
Puma Biotechnology, Inc.	Alisertib	—	RECRUITING	2027-06-30	NCT06369285
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN016	—	RECRUITING	2027-06-30	NCT06942234
Genmab	Rina-S	—	RECRUITING	2027-07	NCT05579366
Incyclix Bio	INX-315	—	RECRUITING	2027-07	NCT05735080
Hummingbird Bioscience	ENV-501	—	RECRUITING	2027-07	NCT06956690
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2027-07-31	NCT07054190
AstraZeneca	AZD8421	—	RECRUITING	2027-08-04	NCT06188520
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	A166	—	RECRUITING	2027-09-20	NCT07299825
AstraZeneca	AZD8205	—	RECRUITING	2027-09-29	NCT05123482
Pfizer	Disitamab vedotin	—	RECRUITING	2027-10-25	NCT06966453
Filamon LTD	A novel hGIIA-Vimentin Inhibitor	—	RECRUITING	2027-10-26	NCT06926075
CSPC Megalith Biopharmaceutical Co.,Ltd.	SYS6023	—	RECRUITING	2027-11-30	NCT07597629
ALX Oncology Inc.	Evorpacept (ALX148)	—	RECRUITING	2027-12	NCT07007559
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
AstraZeneca	Camizestrant	—	RECRUITING	2027-12-03	NCT07427394
Criterium, Inc.	Palbociclib	Kinase Inhibitor [EPC]	RECRUITING	2027-12-31	NCT04567420
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	GTAEXS617	—	RECRUITING	2028-01	NCT05985655
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2028-01-01	NCT07102381
Blue Earth Diagnostics	[18F]FPyQCP	—	RECRUITING	2028-01-31	NCT07432633
Avenzo Therapeutics, Inc.	AVZO-021	—	RECRUITING	2028-01-31	NCT05867251
Ellipses Pharma	EP0062	—	RECRUITING	2028-02	NCT05573126
Shenzhen Ionova Life Sciences Co., Ltd.	INV-6452	—	RECRUITING	2028-02-04	NCT07612891
Aminex Therapeutics, Inc.	AMXT 1501 Dicaprate	—	RECRUITING	2028-02-28	NCT07287917
Forward Pharmaceuticals Co., Ltd.	FWD1802	—	RECRUITING	2028-05-01	NCT07002177
Jiangsu HengRui Medicine Co., Ltd.	Trastuzumab Rezetecan for Injection	—	RECRUITING	2028-06	NCT07497386
ModeX Therapeutics, An OPKO Health Company	MDX2001	—	RECRUITING	2028-08	NCT06239194
Avenzo Therapeutics, Inc.	AVZO-021	—	RECRUITING	2028-08	NCT06998407
Tanabe Pharma America, Inc.	MT-4561	—	RECRUITING	2028-08	NCT06943521
Roche	GDC-4198	—	RECRUITING	2028-08-31	NCT07100106
Shenzhen Majory Biotechnology Co., Ltd.	MR001 Bispecific Antibody for Injection	—	RECRUITING	2028-09-01	NCT07208149
Novartis	ECI830	—	RECRUITING	2028-09-25	NCT06726148
Qilu Pharmaceutical Co., Ltd.	QLS1304 tablet+Fulvestrant or QLC1401	—	RECRUITING	2028-11-02	NCT07235176
Shandong Suncadia Medicine Co., Ltd.	HRS-6208 Capsule	—	RECRUITING	2028-12	NCT07389733
Tubulis GmbH	TUB-030	—	RECRUITING	2028-12	NCT06657222
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2028-12-19	NCT07405801
Acerand Therapeutics (Shanghai) Limited	ACE-86225106 tablet	—	RECRUITING	2028-12-21	NCT06380660
Terremoto Biosciences Inc.	TER-2013	—	RECRUITING	2028-12-30	NCT07109726
Boehringer Ingelheim	Zongertinib	Kinase Inhibitor [EPC]	RECRUITING	2029-01-08	NCT06324357
Faeth Therapeutics	Serabelisib	—	RECRUITING	2029-05	NCT07558733
Delcath Systems Inc.	Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)	—	RECRUITING	2029-05	NCT06875128
Roche	Giredestrant	—	RECRUITING	2029-05-30	NCT04802759
Leeuwenhoek Laboratories Co. Ltd.	—	—	RECRUITING	2029-06-30	NCT07605728
Pfizer	PF-07248144	—	RECRUITING	2029-07-13	NCT04606446
Seagen, a wholly owned subsidiary of Pfizer	disitamab vedotin	—	RECRUITING	2029-07-28	NCT06157892
BioNTech SE	BNT323	—	RECRUITING	2029-08	NCT06827236
Minghui Pharmaceutical (Hangzhou) Ltd	MHB036C for Injection	—	RECRUITING	2029-08	NCT07130383
MBrace Therapeutics	ADC	—	RECRUITING	2029-09-30	NCT07145255
Merck	Patritumab deruxtecan	—	RECRUITING	2029-12-31	NCT06797635
Merck	Patritumab deruxtecan	—	RECRUITING	2030-04-18	NCT06686394
Eli Lilly	STX-478	—	RECRUITING	2030-07	NCT05768139
Roche	Capecitabine	Nucleoside Metabolic Inhibitor [EPC]	RECRUITING	2030-09-30	NCT03424005
Bristol-Myers Squibb	BMS-986507	—	RECRUITING	2031-02-26	NCT06618287
Novartis	GVV858	—	RECRUITING	2031-05-09	NCT07288359
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2031-10-31	NCT07368998
BeBetter Med Inc	BEBT-209 capsules	—	RECRUITING	2026-06-30	NCT06685796
Shandong Suncadia Medicine Co., Ltd.	HRS-8080; Dalpiciclib Isethionate Tablets	—	RECRUITING	2026-06	NCT06167694
RemeGen Co., Ltd.	Disitamab Vedotin Injection	—	RECRUITING	2026-06	NCT06178159
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 for injection	—	RECRUITING	2026-06	NCT06452706
Forward Pharmaceuticals Co., Ltd.	FWD1802	—	RECRUITING	2026-03	NCT06064812
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2025-12-31	NCT06006390
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	VB15010	—	RECRUITING	2025-12-30	NCT06819215
Jiangsu HengRui Medicine Co., Ltd.	HRS-6209 in Combination with Fulvestrant	—	RECRUITING	2025-12	NCT06555068
RemeGen Co., Ltd.	Disitamab Vedotin Injection （18 weeks）	—	RECRUITING	2025-12	NCT06227117
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
RemeGen Co., Ltd.	Disitamab Vedotin for Injection	—	RECRUITING	2025-06-01	NCT06389006
GeneMedicine Co., Ltd.	GM103 (Part A)	—	RECRUITING	2025-05-30	NCT06265025
BriaCell Therapeutics Corporation	BC1 cell line	—	RECRUITING	2025-04-30	NCT06471673

Showing 100 of 448 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M17D1	—	RECRUITING	2026-08	NCT06503783
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
Angiex, Inc.	AGX101	—	RECRUITING	2026-09-06	NCT06440005
Regor Pharmaceuticals Inc.	RGT-419B	—	RECRUITING	2026-09-30	NCT05304962
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-077	—	RECRUITING	2026-10	NCT06609187
DIGMBIO	DM5167	—	RECRUITING	2026-10-30	NCT07101601
Kind Pharmaceuticals LLC	AND019 PO QD	—	RECRUITING	2026-11	NCT05187832
Shanghai Juncell Therapeutics	Engineering Tumor Infiltrating Lymphocytes	—	RECRUITING	2026-11-01	NCT06375187
Exelixis	XB010	—	RECRUITING	2026-11-23	NCT06545331
TerSera Therapeutics LLC	ZOLADEX	GnRH	RECRUITING	2026-11-30	NCT07310420
Iksuda Therapeutics Ltd.	IKS014	—	RECRUITING	2026-12	NCT05872295
Mersana Therapeutics	XMT-1660	—	RECRUITING	2026-12	NCT05377996
ExpreS2ion Biotechnologies	ES2B-C001	—	RECRUITING	2026-12	NCT06746688
NextCure, Inc.	LNCB74	—	RECRUITING	2026-12	NCT06774963
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-12	NCT05470348
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2026-12	NCT05461768
SillaJen, Inc.	BAL0891	—	RECRUITING	2026-12-24	NCT05768932
Nanjing Sanhome Pharmaceutical, Co., Ltd.	SH009	—	RECRUITING	2026-12-30	NCT07390838
SystImmune Inc.	BL-B01D1	—	RECRUITING	2026-12-31	NCT05983432
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2026-12-31	NCT06043466
Orano Med Theranostics, SAS	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Solve Therapeutics	SLV-154	—	RECRUITING	2027-01	NCT06771219
Affibody	[177Lu]Lu-ABY-271	—	RECRUITING	2027-01-01	NCT07081555
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Atridia Pty Ltd.	HRS-6209 Capsules and fulvestrant injection	—	RECRUITING	2027-04-10	NCT07358377
Accent Therapeutics	ATX-295	—	RECRUITING	2027-04-30	NCT06799065
Relay Therapeutics, Inc.	RLY-2608	—	RECRUITING	2027-04-30	NCT05216432
Thena Biotech S.r.l.	THE-0504	—	RECRUITING	2027-05-01	NCT07646106
Normunity AccelCo, Inc.	NRM-823	—	RECRUITING	2027-05-30	NCT07182149
Olema Pharmaceuticals, Inc.	OP-3136	—	RECRUITING	2027-05-30	NCT06784193
BeOne Medicines	BGB-21447	—	RECRUITING	2027-07-30	NCT06756932
NiKang Therapeutics, Inc.	NKT5097 CDK2/CDK4 dual degrader	—	RECRUITING	2027-07-31	NCT07029399
OncoTherapy Science, Inc.	OTS167PO	—	RECRUITING	2027-09	NCT02926690
Biotheryx, Inc.	BTX-9341	—	RECRUITING	2027-09-30	NCT06515470
Totus Medicines	TOS-358	—	RECRUITING	2027-12	NCT05683418
Aktis Oncology, Inc.	[225Ac]Ac-AKY-1189 (therapeutic)	—	RECRUITING	2027-12	NCT07020117
Iambic Therapeutics, Inc	IAM1363	—	RECRUITING	2027-12	NCT06253871
Clasp Therapeutics, Inc.	CLSP-1025	—	RECRUITING	2027-12	NCT06778863
Oscotec Inc.	OCT-598	—	RECRUITING	2027-12	NCT07358806
Sichuan Baili Pharmaceutical Co., Ltd.	Lutetium [177Lu] BL-ARC001	—	RECRUITING	2027-12	NCT07274852
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
Olema Pharmaceuticals, Inc.	Palazestrant	—	RECRUITING	2027-12-31	NCT05508906
Fate Therapeutics	FT836	—	RECRUITING	2028-01	NCT07216105
Novartis	68Ga-DFC413	—	RECRUITING	2028-01-22	NCT07630961
Cellectar Biosciences, Inc.	Iopofosine I 131	—	RECRUITING	2028-02	NCT07311993
Immunomic Therapeutics, Inc.	ITI-5000 mRNA Vaccine	—	RECRUITING	2028-02	NCT07652242
Regor Pharmaceuticals Inc.	RGT-490	—	RECRUITING	2028-04	NCT07524322
Halda Therapeutics OpCo, Inc.	HLD-0117	—	RECRUITING	2028-04-30	NCT07524855
Cogent Biosciences, Inc.	CGT4255	—	RECRUITING	2028-05	NCT07361562
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
Radionetics Oncology	68Ga-R11228	—	RECRUITING	2028-06-01	NCT07121244
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818 and Olaparib will be administered	—	RECRUITING	2028-08-25	NCT07156253
BeOne Medicines	BGB-43395	—	RECRUITING	2028-11	NCT06120283
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	BBO-10203	—	RECRUITING	2028-11	NCT06625775
ProteinQure Inc.	PQ203	—	RECRUITING	2028-12	NCT07190469
General Oncology, Inc.	Melphalan	—	RECRUITING	2028-12	NCT04150042
Alpha-9 Oncology USA Inc.	[177Lu]Lu-A9-0631	—	RECRUITING	2028-12	NCT07661641
Bristol-Myers Squibb	BMS-986500	—	RECRUITING	2028-12-14	NCT06997029
SystImmune Inc.	BL-M07D1	—	RECRUITING	2028-12-15	NCT06293898
Immunome, Inc.	IM-1617	—	RECRUITING	2029-01	NCT07578571
NiKang Therapeutics, Inc.	NKT3964	—	RECRUITING	2029-01	NCT06586957
Avacta Life Sciences Ltd	AVA6103	—	RECRUITING	2029-01	NCT07454642
Boundless Bio, Inc.	BBI-940	—	RECRUITING	2029-02-28	NCT07408089
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS74539	—	RECRUITING	2029-03	NCT07517198
Pfizer	PF-08032562	—	RECRUITING	2029-04-14	NCT07318805
Novartis	68Ga-NNS309	—	RECRUITING	2029-05-09	NCT07261631
Cogent Biosciences, Inc.	CGT6297	—	RECRUITING	2029-07	NCT07383506
AstraZeneca	Autologous, engineered T Cells targeting TP53 R175H	—	RECRUITING	2029-07-31	NCT05877599
BeOne Medicines	BG-75202	—	RECRUITING	2029-09-30	NCT07222267
Conjupro Biotherapeutics, Inc.	SYS6043	—	RECRUITING	2029-12	NCT07424547
IDEAYA Biosciences	IDE574	—	RECRUITING	2030-03-30	NCT07540572
Roche	GDC-0587	—	RECRUITING	2030-06-01	NCT07214662
Novartis	[68Ga]Ga-NNS309	—	RECRUITING	2031-01-15	NCT06562192
Novartis	[177Lu]Lu-DWJ155	—	RECRUITING	2032-05-24	NCT07660055
Novartis	IEV407	—	RECRUITING	2032-06-08	NCT07604571
Epsilogen Ltd	MOv18 IgE	—	RECRUITING	2026-07	NCT06547840
Radionetics Oncology	68Ga-R10602 injection	—	RECRUITING	2026-07	NCT06745804
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B16D1	—	RECRUITING	2026-07	NCT06493864
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818	—	RECRUITING	2026-06-30	NCT06666270
Avacta Life Sciences Ltd	AVA6000	—	RECRUITING	2026-06-15	NCT04969835
OnKure, Inc.	OKI-219	—	RECRUITING	2026-06-01	NCT06239467
Stemline Therapeutics, Inc.	MEN2312	—	RECRUITING	2026-06	NCT06638307
SAPU NANO (US) LLC	Sapu003	—	RECRUITING	2026-06	NCT07369505
A&G Pharmaceutical Inc.	AG-01 Compound	—	RECRUITING	2026-06	NCT05627960
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502 + NHA	—	RECRUITING	2026-05-07	NCT06769425
Edgewood Oncology Inc.	BTX-A51	—	RECRUITING	2026-05	NCT04872166
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502	—	RECRUITING	2026-04-01	NCT05740956
Shanghai Best-Link Bioscience, LLC	BL0175	—	RECRUITING	2026-02-20	NCT06738966
Shandong Boan Biotechnology Co., Ltd	BA1302	—	RECRUITING	2025-12-31	NCT06596915
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2025-12-31	NCT06126406
Chongqing Precision Biotech Co., Ltd	CEA CAR-T cells	—	RECRUITING	2025-12-31	NCT06010862
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 for injection	—	RECRUITING	2025-12	NCT06115902
MBQ Pharma	MBQ-167	—	RECRUITING	2025-10-01	NCT06075810
Shandong Suncadia Medicine Co., Ltd.	HRS-1358	—	RECRUITING	2025-06	NCT05628870
Minerva Biotechnologies Corporation	huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells	—	RECRUITING	2025-01	NCT04020575
BeiGene	BG-68501	—	ACTIVE NOT RECRUITING	2026-08-31	NCT06257264
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03845166
IDEAYA Biosciences	IDE-161	—	ACTIVE NOT RECRUITING	2026-10	NCT05787587
Eli Lilly	LOXO-783	—	ACTIVE NOT RECRUITING	2026-12	NCT05307705
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	ACTIVE NOT RECRUITING	2026-12	NCT05653752

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Breast Cancer

ER (Estrogen Receptor) (27) HER2 (20) EGFR (11) EGFR- (8) dMMR (4) HER2+ (3)

Novel Breast Cancer Drugs by Company (New molecular entities)

14 companies have an FDA-approved novel drug for Breast Cancer.

Roche 3 drugs

PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF

BLA 2020

KADCYLA

ADO-TRASTUZUMAB EMTANSINE

Novartis 2 drugs

LUMICELL 1 drug

PEGULICIANINE ACETATE

TERSERA 1 drug

Pfizer 1 drug

DAIICHI SANKYO INC 1 drug

DATROWAY

DATOPOTAMAB DERUXTECAN-DLNK

BLA 2025

Eli Lilly 1 drug

INLURIYO

IMLUNESTRANT TOSYLATE

GE HEALTHCARE 1 drug

R-PHARM US LLC 1 drug

AstraZeneca 1 drug

+4 more companies

Reformulations (19 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Breast Cancer Drug Targets

Molecular targets of approved and investigational Breast Cancer drugs — 33 targets tracked.

ERBB2 12 RANKL 9 Estrogen Receptor 8 DNA 3 Topoisomerase II 3 Aromatase 3 EGFR 2 RNA 2 PARP1 2 PARP2 2 FKBP-12 2 mTOR 2 Tubulin 2 ERα 2 Hyaluronan 2 +18 more

Biosimilars (13 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

SHANGHAI HENLIUS BIOTECH

2025